ALPHARETTA, Ga — SANUWAVE Health, Inc. (OTCQB:SNWV), announced today the receipt of U.S. Patent Number 9,095,632 from the U.S. Patent and Trademark Office entitled "Methods for Cleaning and Tenderizing Animal Meat with Shock Waves" that has a patent life to September 2030.
The patent includes twenty claims relating to the use of shock waves for elimination of biological contaminants in animal meat and for its tenderization. Shock waves are applied to sealed animal meat in vacuum bags and the cleaning and tenderizing can be done manually or via a controller actuated by a computer. Currently the meat is cleaned and tenderized via refrigeration for days and weeks in specialized rooms, which translates in significant energy costs. Using shock wave technology, the meat can be concomitantly or sequentially cleaned and/or tenderized in a very short period of time, which translates in saving millions of kilowatt-hours of electricity annually.
"This new patent continues to extend the reach of our technology beyond regenerative medicine into food processing field and fits with our long term strategy to maximize the value of our shock wave technology in non-medical fields. The shock wave methods described into this patent save energy and also allow farmers to raise more grass-fed livestock that yield leaner, tougher meat, which can dramatically reduce the demand for energy-intensive feed corn, to mention only few advantages," commented Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE.
SANUWAVE Health, Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 45 patents (issued or pending) in the field of shock waves used in medical and non-medical applications.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Source: SANUWAVE Health, Inc.
